Fig. 3.

Clinical Outcomes for Second-Line Treatments in HER2 + mBC and median number of months-to-event from 2L initiation (index). a Time to treatment discontinuation (TTD) is the time from index to the first of treatment discontinuation or death; patients without the event were censored at the date of last contact or data cut-off (DCO), whichever came first. b Time to next treatment (TTNT) is the time from index to the first of 3L initiation or death; patients were censored the date of last contact or DCO, whichever came first. c real-world Progression-free survival (rwPFS) is the time from index to the first of clinician-confirmed progression or death; patients were censored at 3L initiation, last contact or DCO, whichever came first